远大医药:创新放射性核素偶联药物TLX591-CDx中国III期临床研究完成全部患者入组给药并计划今年内递交上市申请

格隆汇
12 May

格隆汇5月12日丨 远大医药(00512.HK)发布公告,集团用于诊断前列腺癌的创新在研放射性核素偶联药物(RDC)TLX591-CDx (Illuccix, gallium Ga 68 PSMA-11)在中国进行的 III 期临床试验,近日已完成全部患者入组给药,并计划于今年内在中国递交新药上市申请,这是集团在核药抗肿瘤诊疗领域的又一次重要研发进展。该研究是一项单臂、开放标签的 III 期临床...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10